Prexton Therapeutics gets €29m cash inje...Merck Serono spin-out Prexton Therapeutics has closed a Series B financing round cashing in US$31m for pushing Phase II testing of its Parkinsons compound PXT002331. more ➔
Biotechs concerned over EPO rulesLife Sciences stakeholders in Europe and abroad are voicing their concerns about the European Patent Offices initiative to shorten the time for the examination of patents from up to 56 months to 12 … more ➔
Biotech investor plans IPO in LondonBritish life science investor Arix Biosciences is planning an IPO at London Stock Exchange. The London-based investor aims to raise £100m (€116m) to reinvest in innovations in medical science. more ➔
Prize awarded to innovative productsIn early February, at the 20th edition of the Pharmapack Europe event, outstanding products were honoured with the Pharmapack Award. Organiser UBM EMEA also introduced a new Pharmapack Start-up Hub. more ➔
Molecule prevents oedema French researchers have identified a regulator which controls blood vessel permeability. Their findings open up the possibility to develop drugs preventing oedema that occur in large indications such … more ➔
Fighting AMR efficientlyMajor European stakeholders have released statements on how to fight antimicrobial resistance more effectively. Regulatory agencies such as EFSA and EMA call for locally adapted combination strategies … more ➔
uniQure gets FDA breakthrough status for A...Dutch gene therapy specialist uniQure Biopharma BV will be able to rapidly develop its haemophilia B gene therapy AMT-060. Based on data of a Phase I/II safety study, the FDA granted breakthrough therapy … more ➔
IBAM completes US$690m dealBelgian-headquartered IBA Molecular has completed the acquisition of British Mallinckrodts nuclear imaging business summing up to approximately US$690m. more ➔
€500m to push gene therapyGerman Christian democrats have started the election year underpinning their intention to pump money into life science research and into its translation into products. more ➔
Johnson & Johnson to buy Actelion for...Following a month-long take-over poker, J&Js and Actelions boards have agreed to support an all-cash tender offer from J&J in which shareholders are set to receive US$280.08 per share and … more ➔
